Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMP5O1U)

• Drug Name: GSK2696273 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Chronic pain	MG30	Preregistration	[1]
Immunodeficiency	4A00-4A85	Phase 2/3	[2]

• Cross-matching ID: TTD Drug ID: DMP5O1U

Molecule-Related Drug Atlas

Drug(s) Targeting Adenosine deaminase (ADA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cladribine	DM3JDRP	Hairy cell leukaemia	2A82.2	Approved	[4]
Elapegademase	DMS7OU8	Adenosine deaminase defciency	4A01.1	Approved	[5]
Fludarabine	DMVRLT7	Acute myelogenous leukaemia	2A41	Approved	[6]
Pentostatin	DM0HXDS	Acute graft versus host disease	4B24.0	Approved	[6]
OTL-101	DMLMS6J	Severe combined immunodeficiency	4A01.10	Phase 3	[7]
Ex vivo adenosine deaminase-transduced hematopoietic stem cell therapy	DMIREUZ	Immunodeficiency	4A00-4A85	Phase 1/2	[3]
EHNA	DM014WS	Discovery agent	N.A.	Investigative	[8]
3-(6-Amino-purin-9-yl)-6-phenyl-hexan-2-ol	DMZT8QX	Discovery agent	N.A.	Investigative	[9]
3-(6-Amino-purin-9-yl)-8-phenyl-octan-2-ol	DMAIS1D	Discovery agent	N.A.	Investigative	[9]
1-Deaza-Adenosine	DMG0VN6	Discovery agent	N.A.	Investigative	[10]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adenosine deaminase (ADA)	TTLP57V	ADA_HUMAN	Modulator	[3]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033647)
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Clinical pipeline report, company report or official report of GlaxoSmithKline.
• [4] Cladribine: from the bench to the bedside--focus on hairy cell leukemia. Expert Rev Anticancer Ther. 2004 Oct;4(5):745-57.
• [5] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [6] Purine nucleoside analogs in indolent non-Hodgkin's lymphoma. Oncology (Williston Park). 2000 Jun;14(6 Suppl 2):13-5.
• [7] Clinical pipeline report, company report or official report of Orchard Therapeutics.
• [8] Tight-binding inhibitors--IV. Inhibition of adenosine deaminases by various inhibitors. Biochem Pharmacol. 1977 Mar 1;26(5):359-67.
• [9] Adenosine deaminase inhibitors: synthesis and biological evaluation of unsaturated, aromatic, and oxo derivatives of (+)-erythro-9-(2'S-hydroxy-3'R... J Med Chem. 2000 Nov 30;43(24):4694-700.
• [10] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.